Leap Therapeutics Inc
NASDAQ:LPTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Leap Therapeutics Inc
Cash from Operating Activities
Leap Therapeutics Inc
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Leap Therapeutics Inc
NASDAQ:LPTX
|
Cash from Operating Activities
-$60.1m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Operating Activities
$19B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
2%
|
CAGR 10-Years
10%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Operating Activities
$10B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Operating Activities
$10B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
0%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Operating Activities
$3.6B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Operating Activities
$5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
14%
|
CAGR 10-Years
14%
|
|
Leap Therapeutics Inc
Glance View
Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 36 full-time employees. The company went IPO on 2017-01-24. The firm is focused on developing therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. The Company’s clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. When DKN-01 binds to DKK1, an anti-tumor effect can be generated. DKK1 is a cell secreted protein that research has found its role in embryonic development. DKN-01 is an affinity, neutralizing monoclonal antibody targeting DKK1. DKN-01 reduces free DKK1 levels and has demonstrated an anti-tumor effect in preclinical models.
See Also
What is Leap Therapeutics Inc's Cash from Operating Activities?
Cash from Operating Activities
-60.1m
USD
Based on the financial report for Jun 30, 2025, Leap Therapeutics Inc's Cash from Operating Activities amounts to -60.1m USD.
What is Leap Therapeutics Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-18%
Over the last year, the Cash from Operating Activities growth was -20%. The average annual Cash from Operating Activities growth rates for Leap Therapeutics Inc have been -12% over the past three years , -18% over the past five years .
